Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

First Posted Date
2022-02-01
Last Posted Date
2023-11-14
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
57
Registration Number
NCT05217069
Locations
🇩🇪

Ludwig Maximilians University, Munich, Germany

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

First Posted Date
2022-01-14
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
35
Registration Number
NCT05192889
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane

First Posted Date
2021-12-07
Last Posted Date
2024-10-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
22
Registration Number
NCT05146739
Locations
🇺🇸

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

First Posted Date
2021-10-05
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
830
Registration Number
NCT05067283
Locations
🇺🇸

Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States

🇺🇸

START Midwest ( Site 0267), Grand Rapids, Michigan, United States

🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States

and more 63 locations

CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases

First Posted Date
2021-09-30
Last Posted Date
2024-11-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT05062317
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

First Posted Date
2021-09-17
Last Posted Date
2021-09-17
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Target Recruit Count
153
Registration Number
NCT05047991

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date
2021-09-02
Last Posted Date
2024-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT05032183
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

First Posted Date
2021-08-30
Last Posted Date
2024-09-30
Lead Sponsor
National Health Research Institutes, Taiwan
Target Recruit Count
66
Registration Number
NCT05026905
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

China Medical University Hospital, Taichung, Taiwan

🇨🇳

Taichung Veterans General Hospital, Taichung, Taiwan

and more 1 locations

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

First Posted Date
2021-08-24
Last Posted Date
2021-08-24
Lead Sponsor
West China Hospital
Target Recruit Count
69
Registration Number
NCT05018182
Locations
🇨🇳

Sichuan University West China Hospital, Chengdu, Sichuan, China

Role of Folinic Acid in Improving the Adaptive Skills and Language Impairment in Children With Autism Spectrum Disorder

Phase 2
Completed
Conditions
Autism Spectrum Disorder
Interventions
Drug: Folinic Acid
First Posted Date
2021-08-19
Last Posted Date
2021-08-24
Lead Sponsor
Nishtar Medical University
Target Recruit Count
44
Registration Number
NCT05013164
Locations
🇵🇰

Children's Hospital and Institute of Child Health, Multan, Punjab, Pakistan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy